|IACP Files Comments for FDA’s Prescription Requirement Under Section 503A Guidance|
IACP Files Comments for FDA’s Prescription Requirement Under Section 503A Guidance
IACP Members: WE NEED YOU TO COMMENT, TOO!
IACP has submitted comments to FDA regarding the Draft Guidance for Industry: Prescription Requirement Under Section 503A of the Federal Food, Drug, and Cosmetic Act.
"IACP understands and supports the need to protect public health. However, when providing guidance, it is essential that FDA adheres to the plain language of statutes and Congressional intent that preserve patient and prescriber access to vital compounded medications. Compounding for office administration and anticipatory compounding play two vital roles in today’s modern healthcare system and any guidance put forth must address the ability for patients and prescribers to obtain these medications in a timely and economical manner.
Please click here to view IACP's entire comments to FDA.
We Need All Members to Comment!
We need to show FDA and our Congressional representatives how important this issue is for our patients and practitioners. The more comments submitted to FDA, the better. Please make your voice heard.
You are welcome to copy and paste IACP's comments, or simply comment that you support IACP's submitted comments. COMMENTS ARE DUE: by July 18, 2016.
How To Submit Comments for FDA’s Prescription Requirement Under Section 503A Guidance
IACP has put together some how-to instructions on filing FDA comments to make this as convenient as possible for you.
Click here to access How-To Instructions on Filing Comments with FDA.
Email firstname.lastname@example.org with any questions.
Tell us how compounded pharmaceuticals have helped you, someone you know, or how you have helped someone as a practicing compounding pharmacist. Help us protect your continued access to pharmacy compounding!
Share the P3 community and the value and necessity of personalized prescriptions with your friends.